Evidence map›Paper›PMID 34916686›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2021

[Serum interleukin-2 receptor

J Y Tian, X Zhang, G Cheng, Q H Liu, S Y Wang, J He

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

J Y TianDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
X ZhangDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
G ChengDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
Q H LiuDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
S Y WangDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
J HeDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
Peking University · CNPeking University People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the clinical relevance of serum interleukin-2 receptor

methodsOne hundred and seven SLE patients and 39 healthy controls with comparable age and gender were recruited at Peking University People's Hospital from January 2019 to December 2020. Complete clinical data in 107 SLE patients at baseline and follow-up were collected. SLE disease activity index 2000 (SLEDAI-2K) was used to assess the disease activity of the SLE patients. The serum level of IL-2R

resultsThe serum IL-2R

conclusionSerum IL-2R

Indexed as

Lupus Erythematosus, SystemicBiomarkersCase-Control StudiesHumansInterleukin-2 Receptor alpha SubunitBiomarkersIL2RA protein, humanInterleukin-2 Receptor alpha SubunitLupus erythematosus, systemicLupus nephritisReceptor, interleukin-2T-lymphocytes

Identifiers

PMID34916686
PMCPMC8695147
OpenAlexW4200628465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.